Corvus Pharmaceuticals (FRA:C17) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Corvus Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2024 was €-5.70 Mil. Corvus Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Corvus Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Corvus Pharmaceuticals's current FCF Yield % is -6.87%.

The historical rank and industry rank for Corvus Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:C17's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -135.76
* Ranked among companies with meaningful FCF Margin % only.

Corvus Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Corvus Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals FCF Margin % Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Corvus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Corvus Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Corvus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's FCF Margin % falls into.

Corvus Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Corvus Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.979	/	0
	=	%

Corvus Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-5.695	/	0
	=	%

Corvus Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals Headlines

No Headlines